These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 12381370

  • 1. Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum.
    Lanvers C, Vieira Pinheiro JP, Hempel G, Wuerthwein G, Boos J.
    Anal Biochem; 2002 Oct 01; 309(1):117-26. PubMed ID: 12381370
    [Abstract] [Full Text] [Related]

  • 2. A critical analysis of L-asparaginase activity quantification methods-colorimetric methods versus high-performance liquid chromatography.
    Magri A, Soler MF, Lopes AM, Cilli EM, Barber PS, Pessoa A, Pereira JFB.
    Anal Bioanal Chem; 2018 Nov 01; 410(27):6985-6990. PubMed ID: 30155702
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
    Schrey D, Borghorst S, Lanvers-Kaminsky C, Hempel G, Gerss J, Möricke A, Schrappe M, Boos J.
    Pediatr Blood Cancer; 2010 Jul 01; 54(7):952-8. PubMed ID: 20108339
    [Abstract] [Full Text] [Related]

  • 4. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
    Salzer WL, Asselin BL, Plourde PV, Corn T, Hunger SP.
    Ann N Y Acad Sci; 2014 Nov 01; 1329():81-92. PubMed ID: 25098829
    [Abstract] [Full Text] [Related]

  • 5. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
    Tsurusawa M, Chin M, Iwai A, Nomura K, Maeba H, Taga T, Higa T, Kuno T, Hori T, Muto A, Yamagata M, Japanese Children's Cancer and Leukemia Study Group.
    Cancer Chemother Pharmacol; 2004 Mar 01; 53(3):204-8. PubMed ID: 14634792
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
    Vieira Pinheiro JP, Wenner K, Escherich G, Lanvers-Kaminsky C, Würthwein G, Janka-Schaub G, Boos J.
    Pediatr Blood Cancer; 2006 Jan 01; 46(1):18-25. PubMed ID: 15929133
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations.
    Ballerini A, Moro F, Nerini IF, Marzo CM, Di Clemente A, Ferrari M, D'Incalci M, Biondi A, Colombini A, Conter V, Porcu L, Cervo L, Rizzari C, Zucchetti M.
    Cancer Chemother Pharmacol; 2017 Jun 01; 79(6):1267-1271. PubMed ID: 28424964
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Isolation, Purification, Characterisation and Application of L-ASNase: A Review.
    Paul T, Mondal A, Bandyopadhyay TK.
    Recent Pat Biotechnol; 2019 Jun 01; 13(1):33-44. PubMed ID: 30318009
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study.
    Würthwein G, Lanvers-Kaminsky C, Gerss J, Möricke A, Zimmermann M, Stary J, Smisek P, Attarbaschi A, Nath C, Zucchetti M, Rizzari C, Schrappe M, Boos J, AIEOP-BFM ALL 2009 Asparaginase Working Party.
    Ther Drug Monit; 2020 Jun 01; 42(3):435-444. PubMed ID: 32022785
    [Abstract] [Full Text] [Related]

  • 15. Allergic reactions and antiasparaginase antibodies in children with high-risk acute lymphoblastic leukemia: A children's oncology group report.
    Ko RH, Jones TL, Radvinsky D, Robison N, Gaynon PS, Panosyan EH, Avramis IA, Avramis VI, Rubin J, Ettinger LJ, Seibel NL, Dhall G.
    Cancer; 2015 Dec 01; 121(23):4205-11. PubMed ID: 26308766
    [Abstract] [Full Text] [Related]

  • 16. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI.
    Clin Cancer Res; 2004 Aug 15; 10(16):5335-41. PubMed ID: 15328169
    [Abstract] [Full Text] [Related]

  • 17. Immobilization of L-asparaginase into a biocompatible poly(ethylene glycol)-albumin hydrogel: evaluation of performance in vivo.
    Jean-François J, D'Urso EM, Fortier G.
    Biotechnol Appl Biochem; 1997 Dec 15; 26(3):203-12. PubMed ID: 9428158
    [Abstract] [Full Text] [Related]

  • 18. Beta-aspartylpeptides as substrates of L-asparaginases from Escherichia coli and Erwinia chrysanthemi.
    Kelo E, Noronkoski T, Stoineva IB, Petkov DD, Mononen I.
    FEBS Lett; 2002 Sep 25; 528(1-3):130-2. PubMed ID: 12297292
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
    Nath CE, Dallapozza L, Eslick AE, Misra A, Carr D, Earl JW.
    Biomed Chromatogr; 2009 Feb 25; 23(2):152-9. PubMed ID: 18823071
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.